title: Borrelial Lymphocytoma in Adult Patients.
abstract: Information on the course and outcome of borrelial lymphocytoma (BL) is limited.
  
  
  
  The study comprised 144 adult patients (75 female, 69 male; median age, 49 years) who had BL diagnosed at a single center between 1986 and 2014 and were followed up for 1 year.
  
  
  
  BL was located on the breast in 106 patients (73.6%), on the ear lobe in 27 (18.8%), and elsewhere in 11 (7.6%). The median duration of BL before diagnosis was 27 days (interquartile range [IQR], 9-68 days). Concomitant erythema migrans was registered in 104 of 144 patients (72.2%); other objective manifestations of Lyme borreliosis (LB) were present in 11 (7.6%). Immunoglobulin M and/or G borrelial serum antibodies were present in 72 patients (50%). Borreliae were isolated from BL lesions in 14 of 42 patients (33.3%) who had not received antibiotics before skin biopsy. Of 13 typed Borrelia strains, 11 were B. afzelii, 1 was B. garinii, and 1 was B. bissettii The median duration of BL after starting antibiotic treatment was 21 days ([IQR], 10-30 days); the average duration was longer in patients who were older, had longer BL duration before treatment, or had signs of disseminated LB. Treatment failure occurred in 14 of 144 patients (9.7%). Patients with signs or symptoms of disseminated LB before treatment had nearly 4 times higher odds of treatment failure (95% confidence interval, 1.22-13.07) than those without such symptoms. All patients with treatment failure had uneventful outcome after retreatment.
  
  
  
  BL is a rare manifestation of early localized LB. Fourteen-day antibiotic treatment, as used for erythema migrans, is effective.
authors.affiliation: Department of Infectious Diseases, University Medical Center Ljubljana.
authors.forename: Vera
authors.initials: V
authors.lastname: Maraspin
authors.affiliation: Department of Infectious Diseases, University Medical Center Ljubljana.
authors.forename: Mirijam
authors.initials: M
authors.lastname: Nahtigal Klevišar
authors.affiliation: Medical Faculty, Institute of Microbiology and Immunology.
authors.forename: Eva
authors.initials: E
authors.lastname: Ružić-Sabljić
authors.affiliation: Institute for Biostatistics and Medical Informatics, University of Ljubljana, Slovenia.
authors.forename: Lara
authors.initials: L
authors.lastname: Lusa
authors.affiliation: Department of Infectious Diseases, University Medical Center Ljubljana.
authors.forename: Franc
authors.initials: F
authors.lastname: Strle
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015748:Borrelia burgdorferi Group; D001940:Breast / Q000473:pathology; D054644:Ear Auricle / Q000473:pathology; D015787:Erythema Chronicum Migrans / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008193:Lyme Disease / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019310:Pseudolymphoma / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D012867:Skin / Q000473:pathology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents
keywords: Borrelia burgdorferi sensu lato; Lyme borreliosis; borrelial lymphocytoma; outcome; treatment